

# McLeod Health

Place Sticker Here

## Ocrelizumab (Ocrevus) Treatment Plan

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

Height (cm): \_\_\_\_\_ Weight (kg): \_\_\_\_\_ Allergies: \_\_\_\_\_

### Diagnosis:

G35 Relapsing Remitting Multiple Sclerosis  G35 Primary Progressive Multiple Sclerosis

ICD 10 Code: \_\_\_\_\_ Diagnosis Description: \_\_\_\_\_

### Pre-Medications: \*\*administered 30 minutes prior to infusion\*\*

● Acetaminophen 650 mg PO

● Diphenhydramine: Dose:  25 mg  50 mg Route: IVP

● Methylprednisolone: Dose:  40 mg  125 mg Route: IVP

Other (include drug, dose, and route): \_\_\_\_\_

### Drug Orders:

● Ocrelizumab (Ocrevus) (J2350) as directed via IV infusion

Induction: 300 mg IV per Sodium Chloride 0.9% 250 mL on Weeks 0 and 2 (*infused at initial rate of 30 mL/hr and increased by 30 mL/hr every 30 minutes up to a max rate of 180 mL/hr*)

Maintenance: 600 mg IV per Sodium Chloride 0.9% 500 mL once every 6 months x 1 dose (*infused at initial rate of 40 mL/hr and increased by 40 mL/hr every 30 minutes up to a max rate of 200 mL/hr; may start at initial rate of 100 mL/hr and increase by 100 mL/hr every 30 minutes up to a max rate of 300 mL/hr if no infusion reactions occur during the first 3 infusions*) \*schedule first maintenance dose 24 weeks from Week 0 dose\*

● Order Duration: Six months unless otherwise specified (Other: \_\_\_\_\_)

### Lab Orders:

\_\_\_\_\_

### Standing Orders:

● Monitor patient for 1 hour following completion of infusion

● Infusion Reaction Protocol (CPOE-1396) will be activated if any hypersensitivity reaction occurs, including anaphylaxis. Infusion will be stopped and physician notified.

Physician Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Physician Name: \_\_\_\_\_ Phone: \_\_\_\_\_

**Pre-Screening Requirements:**

- Provide Hepatitis screening (Hepatitis B Surface Antigen and Total Hepatitis B Core Antibody) prior to start of therapy and within last 12 months

**Previous Therapies:**

- For new patient referrals, please send history and physical and most recent physician note with completed plan
- If patient has previously received ocrelizumab at another facility, please provide last date received: \_\_\_\_\_
- If patient has previously received another biologic therapy, please provide the name: \_\_\_\_\_ and the last date received: \_\_\_\_\_

**Insurance/Authorization Information:**

Insurance Type: \_\_\_\_\_

Insurance Authorization Reference Number: \_\_\_\_\_

Date Obtained: \_\_\_\_\_ Authorization Valid Until: \_\_\_\_\_

Additional Notes: \_\_\_\_\_

Fax completed Treatment Plan with authorization information to McLeod Infusion Services at the number below or call with any questions.

Florence: 843-777-6001 (Fax)

843-777-4655 (Phone)